An evaluation of copy number variation detection tools from whole‐exome sequencing data
Copy number variation ( CNV ) has been found to play an important role in human disease.
Next‐generation sequencing technology, including whole‐genome sequencing ( WGS ) and …
Next‐generation sequencing technology, including whole‐genome sequencing ( WGS ) and …
Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia
SE Kleinstein, L Heath, KW Makar… - Genes …, 2013 - Wiley Online Library
Arachidonate lipoxygenase (ALOX) enzymes metabolize arachidonic acid to generate potent
inflammatory mediators and play an important role in inflammation‐associated diseases. …
inflammatory mediators and play an important role in inflammation‐associated diseases. …
COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations
…, AJ Resler, B Seufert, K Curtin, SE Kleinstein… - Cancer Causes & …, 2013 - Springer
Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) target the prostaglandin H synthase
enzymes, cyclooxygenase (COX)-1 and COX-2, and reduce colorectal cancer risk. Genetic …
enzymes, cyclooxygenase (COX)-1 and COX-2, and reduce colorectal cancer risk. Genetic …
[HTML][HTML] Transcriptomics of type 2 diabetic and healthy human neutrophils
SE Kleinstein, J McCorrison, A Ahmed, H Hasturk… - BMC immunology, 2021 - Springer
Objectives Chronic inflammatory diseases, including diabetes and cardiovascular disease,
are heterogeneous and often co-morbid, with increasing global prevalence. Uncontrolled …
are heterogeneous and often co-morbid, with increasing global prevalence. Uncontrolled …
Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry
…, AE Coghill, PT Campbell, SE Kleinstein… - Genes …, 2014 - Wiley Online Library
The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) is associated with reduced risk
of colorectal neoplasia. Previous studies have reported that polymorphisms in NSAID‐…
of colorectal neoplasia. Previous studies have reported that polymorphisms in NSAID‐…
Clinical application of whole-genome sequencing in patients with primary immunodeficiency
…, TJ Urban, KM McSweeney, SE Kleinstein… - Journal of Allergy and …, 2015 - jacionline.org
FSY is a PhD student funded by the Medical Research Council; Integrative Toxicology Training
Programme (MRC ITTP) initiative. S.-HK received a Marie-Curie International Incoming …
Programme (MRC ITTP) initiative. S.-HK received a Marie-Curie International Incoming …
Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2)
SE Kleinstein, PR Shea, AS Allen, DM Koelle… - Genes & …, 2019 - nature.com
Herpes simplex virus type 2 (HSV-2) is an incurable viral infection with severity ranging from
asymptomatic to frequent recurrences. The viral shedding rate has been shown as a …
asymptomatic to frequent recurrences. The viral shedding rate has been shown as a …
[PDF][PDF] Impaired host response and the presence of Acinetobacter baumannii in the serum microbiome of type-II diabetic patients
D Perera, SE Kleinstein, B Hanson, H Hasturk… - Iscience, 2021 - cell.com
Type II diabetes (T2D) affects over 10% of the US population and is a growing disease worldwide
that manifests with numerous comorbidities and defects in inflammation. This dysbiotic …
that manifests with numerous comorbidities and defects in inflammation. This dysbiotic …
[PDF][PDF] Whole‐Exome Sequencing Study of Extreme Phenotypes of NAFLD
SE Kleinstein, M Rein, MF Abdelmalek… - Hepatology …, 2018 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable
outcomes. Patients with simple steatosis typically experience a benign course, whereas those …
outcomes. Patients with simple steatosis typically experience a benign course, whereas those …
[HTML][HTML] A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
IR White, SE Kleinstein, C Praet, C Chamberlain… - Plos one, 2022 - journals.plos.org
Certolizumab pegol (CZP) is a PEGylated Fc-free tumor necrosis factor (TNF) inhibitor antibody
approved for use in the treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriatic …
approved for use in the treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriatic …